Leaflet MYTOLAC 60mg solution for injection in pre-filled syringe


Indicated for: acromegaly; neuroendocrine tumors

Substance: lanreotide (somatostatin analogue)

ATC: H01CB03 (Systemic hormonal preparations, excluding sex hormones and insulins | Hypothalamic hormones | Somatostatin and analogues)

Lanreotide is a somatostatin analog used to treat acromegaly and certain neuroendocrine tumors. It works by inhibiting the secretion of hormones such as growth hormone and reducing blood flow to neuroendocrine tumors.

The medication is administered as subcutaneous injections, usually once every 4 weeks, as directed by a doctor. The treatment is effective in controlling symptoms and slowing disease progression.

Side effects may include pain at the injection site, nausea, diarrhea, or fatigue. In rare cases, severe allergic reactions or gallstone formation may occur.

Patients should strictly follow their doctor's instructions and inform them about any other medications they are taking. Pregnant or breastfeeding women should consult a specialist before use.

General data about MYTOLAC 60mg

  • Substance: lanreotide
  • Date of last drug list: 01-09-2021
  • Commercial code: W67786001
  • Concentration: 60mg
  • Pharmaceutical form: solution for injection in pre-filled syringe
  • Quantity: 1
  • Product type: generic
  • Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

  • Manufacturer: PHARMATEN S.A. - GRECIA
  • Holder: AMDIPHARM LIMITED - IRLANDA
  • Number: 13886/2021/01
  • Shelf life: 2 years-after packing for marketing;after openinga pungii-se administreaza imediat

Concentrations available for lanreotide

  • 120mg
  • 30mg
  • 60mg
  • 90mg